Novel biomarker SYT12 may contribute to predicting papillary thyroid cancer outcomes. (22nd September 2017)

• Record Type: Journal Article
• Authors: Jonklaas, J; Murthy, SRK; Liu, D; Klubo-Gwiezdzinska, J; Krishnan, J; Burman, KD; Boyle, L; Carrol, N; Felger, E; Loh, Y P
• Is Part Of: Future science OA. Volume 4:Number 1(2018)
• Publication Date: 2017-09-22
• Subjects: biomarkers -- metastases -- papillary thyroid cancer -- prognosis -- progression -- recurrence -- SYT12; Medicine -- Periodicals; Biotechnology -- Periodicals; 610
• DOI: 10.4155/fsoa-2017-0087
• Languages: English
• ISSNs: 2056-5623

Abstract

Aim: To investigate biomarkers for predicting papillary thyroid cancer outcomes.Materials & methods: The expression of biomarkers ( ITGA2, SYT12 and CDH3 ) was studied in a prospective cohort of patients with papillary thyroid cancer. Three outcomes of initial metastases, baseline status and longitudinal status were analyzed and correlated with the biomarkers.Results: SYT12 provided the best prediction of initial metastasis (sensitivity: 72%; specificity: 54%). SYT12 had the highest accuracy for predicting longitudinal status (sensitivity: 100%; specificity: 47%). The best performance for longitudinal status resulted from combining SYT12 with American Thyroid Association risk stratification, with sensitivity and specificity of 88 and 73%, respectively.Conclusion: SYT12 has some prognostic significance in papillary thyroid cancer. Further validation studies in larger populations are warranted. Lay abstract: Survival and disease recurrence after diagnosis of papillary thyroid cancer is imperfectly predicted by commonly used 'staging systems' based mostly on the characteristics of the tumor such as size and location of spread. Also, these staging systems are generally designed to predict survival. Other characteristics, such as gene mutations may be helpful in predicting whether thyroid cancer will behave aggressively or not. This study investigates three genes associated with thyroid tumors and shows that expression of one of them, synaptotagmin 12 ( SYT12 ), tends to predict greater progression of disease in patients with papillary thyroid cancer.